Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
12 December 2020 | Story André Damons | Photo Supplied
Read More Bianca Vermeulen
Bianca Vermeulen started her journey to become a doctor this year after being accepted by the University of the Free State (UFS) to study medicine. She had previously applied 32 times in eight years to study medicine.

A first-year medical student from the University of Free State (UFS) is finally on her way to realise her childhood dream of becoming a doctor after having been rejected 32 times in eight years to study medicine.

Bianca Vermeulen, who started the MBChB programme in 2020, said she applied 32 times in eight years and got rejected every time. As a qualified Critical Care Clinical Technologist who worked for the Free State Department of Health, the daily interaction with her patients and colleagues inspired her to keep her dream alive.

“My childhood dream (of becoming a doctor) did not fade. Dreams do not have expiry dates. During my time in the clinical setting, I learnt some important life lessons. Experience is most definitely what I got when I did not get what I wanted,” said Vermeulen.

According to her, working in a clinical setting fueled her passion. Said Bianca: “I woke up to an alarm clock of opportunity. At the end of the day I can go home with a feeling of satisfaction. I could not have done it without the support of my colleagues and friends. Then it all becomes worth it.”

Finally, a yes to study medicine

Vermeulen said she was at work when she received an e-mail on 3 October 2019 from the UFS application office. She initially ignored the e-mail thinking they would resend one of their earlier rejection letters. After ‘accidentally’ opening the letter, she could not believe her eyes.

“For a moment I was in denial. I had to read the letter a few times to ensure my eyes were not bewitching me. I had to show a friend to ensure that I had read and understood the letter. Then the reality came as an overwhelming mixture of emotions.”

Studying medicine during a pandemic

Vermeulen , who has a passion for neonatal and paediatric intensive care and would like to specialise in paediatrics and child health care after her undergraduate studies, said she welcomes the change that COVID-19 brought to the academic table.

“Daily routine changed overnight for all people and all stared uncertainty in the face. Students had to adapt to a blended learning approach (which also had its own challenges), but as time progressed, we learnt the new ropes.

“I truly hope that we all take the COVID lessons to heart. In the medical sector, no one is a greater ‘hero’ than another. The sector needs various role players and I hope that people realise the importance of nurses, hospital cleaners, administrative staff and all allied health workers. Without these people, the medical sector cannot function. We all need one another.

“With that being said, I hope people realise that we need a functional system so that we can work with each other and not against a system,” said Vermeulen.

Working with various healthcare workers, she has seen the effects of burnout and experienced the best (and worst) of both worlds but is still happy with her choice to study medicine.

It only takes one successful application

“As [US educator] Randy Pausch said: ‘The brick walls are there for a reason. The brick walls are not there to keep us out. The brick walls are there to give us a chance to show how badly we want something.’ I take this to heart,” Vermeulen said.

“You might have received ample unsuccessful applications, but it will only take one successful application to commence with your dream. If it is truly something you want to do, never give up on your dreams. Always work hard and take to heart what the Lord has done for you!”

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept